The objective of this study was to identify associations of the cholesteryl ester transfer protein (CETP) gene with coronary artery disease (CAD) with tagging (t) single nucleotide polymorphisms (SNPs) chosen to optimally account for intra-genic variation.
Coronary artery disease (CAD) and its clinical manifestation, myocardial infarction (MI), are etiologically complex, with approximately equal contributions from genetic and environmental factors (1, 2) . The genetic component of CAD is believed to include modest contributions from common genetic variants in multiple genes, but few associations of common single nucleotide polymorphisms (SNPs) have been consistently replicated and the genetic basis of CAD remains obscure (3) . Inadequate sample size and poor phenotypic and genetic characterization undoubtedly have contributed to this dilemma. Also, the unexpected finding that multiple less common, non-synonymous variants (i.e., for PCSK-9, ABCA1, APOA1, and LCAT) explain a major portion of population variance of low-density lipoprotein (LDL) or high-density lipoprotein (HDL) has challenged the "common disease, common variant" hypothesis (4, 5) .
The 22-kilobase cholesteryl ester transfer protein (CETP) gene, located on chromosome 16q21, specifies a 493 amino acid protein, expressed in multiple tissues, that localizes in the circulation primarily on larger, lipoprotein-AI-containing HDL-cholesterol (C) particles, where its principal role is to catalyze the exchange of triglycerides (TG) on apoB-containing particles (e.g., LDL-C, very LDL-C) for cholesteryl esters from HDL-C (6). Higher CETP concentrations typically are associated with lower HDL-C (7, 8) . TaqIB and other variants of CETP have been associated with reduced CETP activity. However, despite the consistent association these variants have with higher HDL-C levels, their clinical phenotype remains uncertain (9) . The previous postulate that CETP activity is inversely related to CAD risk (10 -15) has been challenged by the recent, unexpected finding that pharmacological inhibition of CETP (16) increases cardiovascular risk (17) .
Given the critical role of CETP in reverse cholesterol transport and hence potentially in CAD risk, this study comprehensively evaluated CETP genetic variation via SNPs and SNP haplotypes in a large, angiographically phenotyped patient cohort. The goal was to better define CETP genotypephenotype associations and optimally capture both common and uncommon genetic variation (18, 19) with a recently described set of tagging (t) SNPs (20) .
Methods
Study population. The study population included patients undergoing coronary angiography at hospitals within the Utah-based Intermountain Healthcare system who consented to participate in the cardiac catheterization registry of the Intermountain Heart Collaborative Study. Between August 1994 and June 2004, a cohort of 10,020 patients (men and women) underwent angiography and were enrolled in the registry. The study was approved by the LDS Hospital's Institutional Review Board. Assessment of CAD. The presence of CAD, the primary study end point, was determined by standard coronary angiographic procedures. The patient's angiogram was graded by a cardiologist (who was unaware of genetic test results). Patients were categorized as being free of CAD (i.e., free of CAD or with minimal, Ͻ10% stenosis), having moderate CAD (i.e., most severe lesion 10% to 69% stenosis), or having significant CAD (i.e., Ն1 lesion of Ն70% stenosis). Moderate CAD was classified as an indeterminate phenotype and patients in that group were excluded from statistical analyses. Because it is the most clinically relevant phenotype and the decision to treat is based on the presence of flow-limiting lesions (i.e., Ն70% stenosis), CAD presence was defined as those with significant CAD, and non-CAD control subjects were those patients free of CAD. Secondary end points. The secondary end point of MI was defined as any MI in the patient's prior history or on hospital admission. The MI events were determined from Intermountain Healthcare's electronic record repository and were ruled-in by electrocardiography and/or biomarker measurements. An MI was defined by biomarkers as a creatine kinase-myocardial band (CK-MB) Ͼ6 mg/dl and a CK-MB index Ͼ3% in the appropriate clinical setting. For MI association analyses, the subgroup of patients with moderate CAD was included.
Lipid measurements were also evaluated as secondary end points. Total cholesterol (TC) and TG were measured from fasting blood samples drawn during hospital stay but before angiography with dry-slide technology on a VITROS 950 analyzer (Ortho Clinical Diagnostics, Raritan, New Jersey). The HDL-C was measured after sample treatment with VITROS HDL-Cholesterol Magnetic Reagent. The LDL-C was calculated from those values. Clinical information. Demographic and health history data were obtained from physicians and hospital records and stored in a research database. These data included age, gender, smoking status, hypertension, hyperlipidemia, diabetes, and family history of early CAD or MI. Smoking was considered present for active smokers or those with a Ͼ10 pack-year history. Prevalent diabetes mellitus, hyperlipidemia, and hypertension were physician-reported from clinical and laboratory findings or were based on current use of relevant medications. For laboratory findings, diabetes was defined as a fasting blood sugar Ն126 mg/dl, hypertension as systolic blood pressure Ն140 mm Hg or diastolic blood pressure Ն90 mm Hg, and hyperlipidemia as fasting TC Ն200 mg/dl or LDL-C Ն130 mg/dl. Patient-reported family history was positive if a first-order relative had suffered cardiovascular death, MI, or coronary revascularization before age 65 years. Genotyping. Previously, sequence variation in the CETP gene was determined among 50 unrelated individuals in the promoter, 16 exons, exon-intron boundaries, and 3= untranslated region (20) . From 32 SNPs, 11 tSNPs were selected from 7 linkage disequilibrium (LD) groups (20) with an analysis method that evaluated inferred haplotypes from 339 unrelated individuals (19) . Those 11 tSNPs were included in this study. Haplotypes were determined from these tSNPs as discussed in the next section.
Genotyping of rs1800776 (C-631A) and rs11076175 (MspI) was performed with Simple Probe chemistry and melt curve analysis on the Light Typer (Roche Diagnostics, Indianapolis, Indiana). The other tSNPs were genotyped with 5= exonuclease (Taqman) chemistry on the ABI Prism 7000 (Applied Biosystems, Foster City, California). Assay Study hypothesis and design. The primary study hypothesis was that 1 or more of the 11 tSNPs or a tSNP-defined haplotype would predict an altered risk of angiographic CAD. Secondary end points of interest were MI and lipid levels (e.g., HDL-C). Study patients were separated a priori into three mutually exclusive groups, with the primary study population being nondiabetic, nonsmoking patients. To reduce unwanted variation from non-cholesterol genetic and environmental factors, diabetic patients and smokers were excluded from the primary analysis and evaluated as secondary study populations as: 1) any smoker, and 2) nonsmoking diabetic patients (mutually exclusive). Analysis was restricted to those patients with complete genotypic data for all 11 tSNPs. Statistical considerations. Differences in CAD diagnosis and MI were evaluated for each tSNP by the chi-square test. Multivariable logistic regression provided adjusted odds ratios (ORs) and 95% confidence intervals (CIs) after forced entry of covariables (age, gender, cardiac risk factors). Adjustment also was made in other models for TC, LDL-C, HDL-C, TG, and self-reported ethnicity. Evaluation of tSNP associations with lipid levels was performed by Student t test (TG level was log-transformed first).
Haplotype-defining tSNP groups were assigned a priori on the basis of prior LD group findings (20) . Inference of phased haplotypes and comparison of haplotype frequency differences between patients with and without CAD or MI was performed with SimHap and on the basis of 1,000 simulations. Haplotypes of frequency Ͼ0.01 that contained a variant allele were compared with the LD group's wildtype haplotype. Extended haplotypes with tSNPs from multiple LD groups were then evaluated to find the best CAD risk-discriminating haplotypes. Haplotype analyses did not employ multivariable adjustment, owing to software restrictions. Finally, association analyses were performed at the patient level to obtain ORs for the best haplotypes on the basis of carriage of 0, 1, or 2 copies of the haplotype (ignoring phase uncertainty).
Pair-wise LD was calculated and plotted with Haploview. Other statistical analyses were performed with SPSS (version 13.0; SPSS Inc., Chicago, Illinois). Two-tailed p values were designated as significant for p Յ 0.00485 on the basis of correction for multiple comparisons of the 11 tSNPs (20) and were considered suggestively associated for p Յ 0.05.
Results
Of the 10,020 available patients, a total of 9,692 had a sufficient quantity of deoxyribonucleic acid to be considered for this study. Of these, 8,382 patients (86%) had full genotypic data available. Sixty-seven percent of patients had CAD. Patient risk factors and ethnicity are shown in Table 1 . Each traditional risk factor predicted CAD at p Ͻ 0.001. Genetic associations in the primary population (nonsmoking, nondiabetic patients). Of the 6,190 nondiabetic, nonsmoking patients, 4,811 were included (666 were excluded owing to the moderate CAD phenotype and 713 owing to missing Ն1 genotype). Pair-wise LD between the 11 tSNPs is shown in Figure 1 . Various tSNP associations with TC, LDL-C, HDL-C, and TG were found (Table 2) .
Single tSNP analyses (Table 3 ) identified a significant allelic association with CAD for tSNP Tϩ1086A (p ϭ 0.0034). An additive genetic model was suggested (OR ϭ 0.84 for TA and OR ϭ 0.64 for AA, vs. TT. See online Table 1 for details). In addition, the tSNPs C-631A and Gϩ2389A had suggestive allelic associations (Table 3) Non-Caucasian 4% 5% 5% Unknown 6% 8% 6% *These sample sizes are for the primary end point of coronary artery disease (CAD). For the end point of myocardial infarction (MI), wherein patients with an indeterminate CAD phenotype were included, sample sizes were increased to n ϭ 5,477 (MI cases: 30%) for nonsmoking nondiabetic patients, n ϭ 1,637 (MI cases: 37%) for smokers, and n ϭ 1,430 (MI cases: 35%) for nonsmoking diabetic patients.
1.21, p ϭ 0.003). Adjustment for age, gender, hypertension, hyperlipidemia, and family history left no associations at p Ͻ 0.00485 (Tϩ1086A: adjusted p ϭ 0.042), primarily owing to age, but the small changes in the beta-coefficients suggested a lack of strong confounding and a potential loss of precision due to addition of terms to the model. Interestingly, despite the biologic plausibility of a confounding effect, adjustment for hyperlipidemia and for TC, LDL-C, HDL-C, or TG did not confound tSNP associations nor did adjustment or stratification by ethnicity (data not shown).
In haplotype analyses, significant CAD differences were found in LD group B (Table 4) for the haplotype ATC (p ϭ 0.0017 vs. wild-type TCC) across tSNPs Tϩ1086A, Cϩ878T, and Cϩ408T, with OR ϭ 0.85 and OR ϭ 0.60 for carriage of 1 or 2 ATC haplotypes, respectively. Suggestive CAD significance was found for LD group A (haplotype AAA of tSNPs C-631A, MspI, and Gϩ2389A, p ϭ 0.013 vs. wild-type; OR ϭ 1.17 and OR ϭ 2.78 for carriage of one or two copies, respectively) and LD group C (AG haplotype of tSNPs Tϩ1086A and NlaIII, p ϭ 0.011 vs. wild-type; OR ϭ 0.83 and OR ϭ 0.70 for carriage of one or two copies, respectively). Haplotypes ATC (LD group B) and AAA (LD group A) showed independent associations (data not shown). Haplotype analysis combining tSNPs from LD groups A and B resulted in a 6-tSNP haplotype wherein the variants from the CAD-associated haplotypes previously mentioned were mutually exclusive, and the 6-tSNP haplotype associations were of similar or weaker significance (data not shown), suggesting independence of effect for LD groups A and B.
The LD group C haplotype AG was associated with higher HDL-C (mean 54. showed a weak association of tSNP TaqIB with CAD. The association was moderately reduced by adjustment for traditional risk factors (p ϭ 0.12) and eliminated by adjustment for tSNPs C-631A, MspI, Tϩ1086A, Cϩ878T, Gϩ2389A, and Cϩ408T (OR ϭ 1.04, p ϭ 0.74). In the LD group D haplotype to which TaqIB belongs, some potential associations were suggested, but the evidence was spread across multiple haplotypes (Table 4) . Haplotypes across LD groups A, B, and D were considered (i.e., by adding TaqIB to the 6 tSNPs previously mentioned), but this did not increase the discriminatory power of any haplotype. Instead, the CAD association evidence for the 6-tSNP CAATGC haplotype from LD groups A and B was split between two 7-tSNP haplotypes (data not shown). Association with MI. Thirty percent of patients had experienced an MI (Table 1) . No single tSNP was associated with MI after correction for multiple tests (online Table 2 ), and no haplotype was associated with MI (online Table 3 ). Tables 8  to 11 ), and when pooled with the primary population, an interaction of smoking with Aϩ1825C was suggested (test of interaction: p ϭ 0.001).
Discussion

Summary of findings.
Among a large population of nondiabetic non-smokers at risk for CAD, the tSNPs Tϩ1086A, C-631A, and Gϩ2389A of CETP showed allelic and genotypic associations with angiographic CAD. Furthermore, the haplotype defined by tSNPs ϩ1086A, ϩ878T, and ϩ408C was associated with lower CAD risk, and an independent association with higher CAD risk was suggested for the haplotype defined by Ϫ631A, MspIA, and ϩ2389A. These findings suggest the presence of two directionally different causal variants within or near the CETP gene and on separate haplotypes. They also suggest that CETP genetic risk is complex and characterized by allelic heterogeneity. Adjustment for traditional risk factors diminished some of the genetic associations. However, because genotype (present since conception) predates the appearance of clinical risk factors, it can be argued that unadjusted genetic risk Average (؎SD) TC, LDL-C, HDL-C, and TG Levels by tSNP Allele Carriage Horne et al. May 22, 2007 May 22, :2053 CETP tSNPs, tSNP Haplotypes, and Clinical CAD Risk might be more relevant to pathophysiological considerations (i.e., with genes potentially explaining risk factors rather than the reverse). In contrast, TC, LDL-C, HDL-C, and TG concentrations did not affect tSNP associations, although several tSNP associations with lipid levels were found. Thus, some of the CETP tSNP effects might relate to mechanisms beyond lipid concentrations, including lipoprotein functionality. Rationale for elucidating genetic associations. Elucidation of the genetic underpinnings of CAD is of major scientific interest because: 1) it can provide crucial insights into disease pathogenesis; 2) it might be applied to individual risk prediction ("individualized medicine"); 3) it can stimulate the discovery of therapeutic interventions (i.e., guiding interventions directed at specific genes, gene products, or pathways); and 4) it underlies the pharmacogenetics of individual patient-drug interactions (3, 21) . A logical approach to the discovery of genetic factors for CAD is to focus on genes in biologic pathways implicated in disease pathophysiology (3, 22) . Topol et al. (22) divided these into four over-arching (and interdependent) pathways: lipid metabolism, arterial inflammation, endothelial integrity, and thrombosis. The CETP gene represents a critical element in the lipid metabolic pathway; hence, understanding its potential contribution to genetic risk is crucial. However, despite the consistent association of CETP variants (including the common and well-studied TaqIB) with HDL-C levels, their impact on CAD end points remains obscure (9, 23) . Adding to the uncertainty about CETP 's role in CAD risk is the recent unexpected observation that pharmacological inhibition of CETP (i.e., with torcetrapib) (16) increases cardiovascular risk (17) , whereas CETP activity previously had been postulated to be inversely related to CAD risk (10 -15) . Reasons for past failures. A number of reasons have been proposed for the frequent failure to replicate SNP associations (24, 25) . One is the testing for associations in adequately large samples so as to minimize both Type I (false positive) and Type II (false negative) errors. A second problem is inadequate characterization and standardization of study populations, including imperfect ascertainment of clinical phenotypes, mixed genetic background of patients (e.g., population stratification), and evaluation of differing outcomes (i.e., CAD vs. MI). Another is a failure to address the problem of multiple comparisons with prospective, restrictive testing with adequate statistical correction. Still another source of complexity is the frequent dissociation of intermediate biomarkers (i.e., lipids/lipoproteins) and clinical outcomes (angiographic CAD or MI) (9, 23, 26) .
In addition, a tested SNP might not be biologically functional but a marker of a functional variant in some but not other populations (18, 19) . Notably, CETP promoter SNP C-629A (and many other promoter SNPs) is in high LD with TaqIB (20, 27) . Furthermore, tSNP Cϩ878T is in almost exact LD with exonic SNP I405V, whereas tSNP Tϩ1086A resides on a subset of haplotypes containing those and 6 other SNPs (20) . When functional SNPs are unknown, tests of variants in LD groups (i.e., clusters of variants that are linked/co-inherited) might more reliably characterize susceptibility (19, 28) .
Finally, the basic assumption in previous studies of "common disease, common variants" might not be generally correct. This hypothesis (29) (32) and locus heterogeneity. Indeed, multiple less common, nonsynonymous variants in PCSK-9, ABCA1, APOA1, and LCAT have recently been reported to explain a major portion of population variance of LDL-C or HDL-C, further challenging the common disease, common variant hypothesis (4, 5) . Present rationale. This study was designed to address several weaknesses of previous SNP association studies. The study was large, providing power to discover modest risk associations and reduce error. Sources of statistical noise (e.g., smoking) were excluded. Multiple comparisons were addressed by appropriate statistical correction. Relevant clinical end points (angiographic CAD, clinical MI) rather than biomarkers (lipids) were assessed and tested separately. The SNPs were selected from a comprehensive study (20) so as to maximally account for genetic variation in CETP.
Together, testing of single tSNPs and of haplotypes can be complementary. If single tSNPs are themselves diseaseassociated, they could represent the most powerful disease markers (33) . In contrast, if they are not and/or if several functional SNPs exist in close proximity and interact, then haplotypes could represent superior markers (28) . This study tested for both, with tSNPs as an appealing set of markers to address the first argument and haplotypes of tSNPs to address the latter. Finally, our study size allowed us to address possible associations of less common as well as the more common CETP polymorphisms with CAD and MI risk. Implications of study findings. Similar to several other lipid-metabolic genes (4, 5) , multiple less common CETP variants (MAF ϭ 0.01 to 0.20) were associated herein with CAD risk (e.g., C-631A and Tϩ1086A). This finding, taken together with the previous examples, indicates that the "common variant common disease" hypothesis does not always hold and should not be assumed. Because SNPs with lower MAF necessarily require greater power to detect associations than very common SNPs, candidate gene studies should be much larger than previously envisioned (i.e., powered to adequately evaluate MAFs of 0.01 to 0.20). Although they require replication and extension, these findings revise the understanding of CETP with respect to CAD pathogenesis, therapeutic insights, individual risk predictions, and, eventually, individualized pharmacogenetics. TaqIB and the present study. The CETP TaqIB has been evaluated extensively with varied results (e.g., see references 7,8,10 -12,34,35) and a modest overall association in metaanalysis (15) . In the present study, an apparent TaqIB association with CAD (genotypic OR ϭ 0.86, p ϭ 0.08) of similar magnitude to prior reports (15) was eliminated by adjustment for other tSNPs. The confounding of TaqIB resulted primarily because the minor alleles of two tSNPs associated with CAD (C-631A, Gϩ2389A) were not on the haplotypes containing the protective TaqIB variant allele and because the variant alleles of the tSNPs associated with lower CAD risk (Tϩ1086A, Cϩ878T) were coincident with the TaqIB variant. This suggests that previous TaqIB associations likely arose as a result of multiple other CETP variants that are in LD with TaqIB. Thus, TaqIB is a less precise marker of CAD risk than the combination of multiple other less common CETP SNPs and should be replaced by these markers in future studies. Study limitations. Not all CETP SNPs might be "tagged" by the 11 tSNPs, although they were selected to optimally account for genetic variation in coding and functional regions. Observational studies are subject to potential selection bias, and registry patients were at higher CAD risk than the general population. However, important potential confounders were dealt with by design (smoking and diabetes) or by multivariable adjustment (for other risk factors). The study consisted primarily of Caucasians, and the results might not apply equally to other ancestral groups. The functional effect of tSNP alleles was not directly assessed, but associations with lipid levels might be an indirect marker of functional activity (also, LD group B tSNPs are in LD with I405V and TaqIB [20] , which decrease CETP mass [7, 34] ; MspI in LD group A might increase mass [7, 34] ).
Conclusions
Multiple, less common CETP tSNPs and tSNP-defined haplotypes were associated with angiographically defined CAD, thus the association of CETP with CAD might operate through allelic heterogeneity or haplotype-specific mechanisms. The protective effect previously reported for TaqIB was fully accounted for by other tSNPs, suggesting that TaqIB might imperfectly mark the risk carried by multiple less-frequent CETP variants. The study also illustrates that comprehensive candidate gene evaluations using tSNPs or tSNP haplotypes might explain previously reported associations; this approach should be applied to other risk-associated genes. Although these findings should be independently validated, they mark an advance in understanding CETP-related pathophysiology and CAD risk. Finally, CETP tSNPs should be combined with those of other lipid metabolism genes and, subsequently, genes in other atherosclerosis pathways to build a comprehensive estimate of CAD genetic risk (36) .
